First-Line Serplulimab in Extensive-Stage Small Cell Lung Cancer: Secondary Analysis of the ASTRUM-005 Phase 3 Randomized Clinical Trial

Background

Extensive-stage small cell lung cancer (ES-SCLC) is an aggressive form of lung cancer that has usually spread beyond one side of the chest at the time of diagnosis. It tends to grow quickly and, without treatment, can lead to rapid clinical decline. For many years, the standard first-line treatment has been platinum-based chemotherapy, most commonly carboplatin or cisplatin combined with etoposide. Although this approach can shrink tumors and relieve symptoms, relapse is common and long-term survival remains limited for most patients.

Serplulimab is a humanized anti-PD-1 monoclonal antibody. By blocking the PD-1 pathway, it helps restore the immune system’s ability to recognize and attack cancer cells. In the original ASTRUM-005 phase 3 trial, adding serplulimab to chemotherapy improved survival compared with chemotherapy alone. The secondary analysis reported here examines whether that benefit persisted with longer follow-up and whether patient-reported outcomes and exploratory biomarker findings supported the clinical results.

Study Design and Participants

ASTRUM-005 was an international, double-blind, randomized phase 3 clinical trial conducted in China, Russia, Ukraine, Poland, Turkey, and Georgia. Patients were enrolled from September 12, 2019, through April 27, 2021. Eligible participants had histologically or cytologically confirmed ES-SCLC and had not received prior systemic therapy.

A total of 585 patients were randomly assigned in a 2:1 ratio: 389 patients received serplulimab plus chemotherapy, and 196 received placebo plus chemotherapy. The chemotherapy backbone consisted of carboplatin and etoposide given every 3 weeks for up to 4 cycles. After the chemotherapy phase, treatment continued according to the protocol, with serplulimab or placebo given as maintenance.

The median age of participants was 63 years in the serplulimab group and 62 years in the placebo group. Baseline characteristics were generally well balanced between groups, supporting a fair comparison of outcomes.

Main Findings

With an extended follow-up through May 7, 2024, the median follow-up duration was 42.4 months. At data cutoff, overall survival events had occurred in 280 patients in the serplulimab group and 166 patients in the placebo group.

The survival results remained clearly favorable for serplulimab. Median overall survival was 15.8 months in the serplulimab group compared with 11.1 months in the placebo group. This corresponded to a hazard ratio of 0.60, indicating a 40% relative reduction in the risk of death, with strong statistical significance.

Long-term survival was also better in the serplulimab group. The 4-year overall survival rate was 21.9% with serplulimab versus 7.2% with placebo. For a disease such as ES-SCLC, where durable survival has historically been uncommon, this difference is clinically meaningful and suggests that a subset of patients may derive lasting benefit from immunotherapy combined with chemotherapy.

Safety

The safety profile was consistent with the known toxicities of the regimen. Grade 3 or higher treatment-emergent adverse events related to serplulimab or placebo occurred in 35.0% of patients in the serplulimab group and 29.1% in the placebo group.

In practical terms, this means serious side effects were somewhat more frequent in the serplulimab arm, but the overall safety findings did not reveal new concerns beyond what is expected from combining immunotherapy with platinum-based chemotherapy. As with other PD-1 inhibitors, clinicians should remain alert for immune-related adverse events affecting organs such as the lungs, liver, thyroid, skin, and intestines, even though the abstract did not report unexpected safety signals.

Patient-Reported Outcomes

An important part of modern cancer research is understanding how patients feel and function during and after treatment. In this analysis, patient-reported outcomes suggested consistent trends toward improved overall health, less shortness of breath, and less pain in both groups over time, with faster recovery from alopecia in the serplulimab group.

These findings are relevant because survival benefit alone does not fully capture treatment value. Improvements in symptoms such as dyspnea and pain can meaningfully affect daily life, particularly in a cancer that often causes cough, breathing difficulty, chest discomfort, and fatigue. Faster recovery from hair loss may also reduce the emotional burden of treatment for some patients.

Interpretation

This secondary analysis strengthens the evidence that serplulimab plus chemotherapy should be considered a first-line standard option for previously untreated ES-SCLC. The main reason is not only that median survival improved, but that the benefit persisted over years of follow-up, with a notable fraction of patients alive at 4 years.

That durability matters. In small cell lung cancer, early tumor control has long been possible, but long-term disease control has been rare. Immunotherapy appears to be helping a subset of patients achieve more durable responses, likely by enabling the immune system to maintain pressure on microscopic residual disease after chemotherapy has reduced tumor burden.

The study also supports the broader oncology shift toward combining chemotherapy with immune checkpoint blockade in first-line treatment for ES-SCLC, similar to the approach already adopted in several other metastatic solid tumors. For clinicians, this means serplulimab adds to the modern treatment toolkit when the goal is both symptom relief and longer survival.

Exploratory Biomarker Considerations

The abstract notes exploratory biomarker findings, though detailed results are not provided here. In trials like ASTRUM-005, biomarker analyses typically aim to identify features that may predict who benefits most from treatment, such as tumor immune microenvironment characteristics, PD-L1 expression, or other molecular signals.

At present, however, no biomarker has replaced clinical judgment in selecting first-line therapy for ES-SCLC. Most patients who are eligible for treatment are considered candidates for immunotherapy plus chemotherapy, unless contraindications exist. Future biomarker work may help personalize therapy further and identify patients more likely to achieve long-term benefit.

Clinical Significance

From a practical standpoint, this study offers several important takeaways. First, it confirms that the serplulimab regimen is not only effective early on but also capable of producing sustained survival gains. Second, the safety profile remains manageable and broadly consistent with prior experience. Third, patient-reported outcomes suggest that the regimen may support better symptom control and recovery during the treatment journey.

For patients and families, the message is cautiously hopeful. ES-SCLC remains a serious and life-threatening disease, and treatment still requires close monitoring. Yet the addition of serplulimab provides a meaningful advancement, offering more patients the possibility of living longer and, for some, living longer with better quality of life.

Limitations

As with all secondary analyses, there are limitations to keep in mind. The study was conducted under a randomized and double-blind design, which is a major strength, but results still reflect a specific trial population and protocol. Real-world patients may be older, frailer, or have more comorbidities than those enrolled in clinical trials.

The abstract also does not provide full details about all biomarker findings, subgroup effects, or the complete spectrum of immune-related toxicities. Those details would be important for a deeper clinical interpretation. In addition, while the 4-year survival rate is encouraging, the majority of patients still experienced disease progression or death, underscoring the need for continued research.

Conclusion

With extended follow-up, ASTRUM-005 shows that first-line serplulimab added to carboplatin and etoposide produces durable overall survival benefit in previously untreated patients with extensive-stage small cell lung cancer. The treatment also appears to support favorable patient-reported outcomes, with no new major safety concerns identified.

Taken together, these findings reinforce serplulimab plus chemotherapy as an important first-line standard of care for ES-SCLC and highlight the continuing role of immunotherapy in improving outcomes for one of the most challenging lung cancers to treat.